Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Neuronetics, Inc. - Common Stock
(NQ:
STIM
)
2.790
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neuronetics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Monday's After-Market Session
October 06, 2025
Via
Benzinga
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
September 17, 2025
Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services
From
Neuronetics
Via
GlobeNewswire
Neuronetics Inc (NASDAQ:STIM) Reports Mixed Q2 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss
August 05, 2025
Neuronetics (STIM) reported mixed Q2 2025 results, beating revenue estimates but posting a wider-than-expected loss, causing a 9% pre-market drop. Greenbrook clinics hit record revenue.
Via
Chartmill
Earnings Scheduled For August 5, 2025
August 05, 2025
Via
Benzinga
Earnings Scheduled For May 6, 2025
May 06, 2025
Via
Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
July 30, 2025
Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world’s largest TMS outcomes dataset
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program
June 10, 2025
NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company’s ongoing commitment to clinical innovation and excellence
From
Neuronetics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 27, 2025
Via
Benzinga
Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month
May 14, 2025
From
Neuronetics
Via
GlobeNewswire
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression
March 31, 2025
Policy update increases access for millions covered by Evernorth Health Services
From
Neuronetics
Via
GlobeNewswire
Earnings Scheduled For March 4, 2025
March 04, 2025
Via
Benzinga
What's going on in today's pre-market session
February 07, 2025
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 07, 2025
Via
Benzinga
These stocks are moving in today's after hours session
February 06, 2025
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
January 29, 2025
Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools
From
Neuronetics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 12, 2024
Via
Benzinga
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
October 14, 2024
Data selected for oral presentation reinforce previous findings on safety and efficacy
From
Neuronetics
Via
GlobeNewswire
Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
September 25, 2024
Policy update increases access for millions covered by HCSC BlueCross BlueShield policies
From
Neuronetics
Via
GlobeNewswire
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
September 19, 2024
BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Releases Software Upgrades to Elevate Patient Care
September 16, 2024
Upgrades improve communication, streamline data management, and strengthen security
From
Neuronetics
Via
GlobeNewswire
Retractable Technologies And 2 Other Penny Stocks Executives Are Buying
September 09, 2024
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enstar Group Limited (Nasdaq – ESGR), PetIQ, Inc. (Nasdaq – PETQ), Greenbrook TMS, Inc. (OTC – GBNHF), GSE Solutions, Inc. (Nasdaq – GVP)
September 06, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories
September 03, 2024
NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives
From
Neuronetics
Via
GlobeNewswire
Butterfly Network And 3 Other Stocks Under $2 Executives Are Aggressively Buying
September 03, 2024
Via
Benzinga
NeuroStar® Marks Two Years of Transformative Impact with NeuroStar University
August 20, 2024
Celebrating milestones in patient care and practice enhancement through NeuroStar’s innovative training facility
From
Neuronetics
Via
GlobeNewswire
Gold Gains Over 1%; Starbucks Shares Move Higher
August 12, 2024
Via
Benzinga
Noninvasive Treatment Provider Neuronetics Agrees To Merge With Canadian Firm Greenbrook TMS; Reports Q2 Earnings And Guidance Below Expectations
August 12, 2024
Neuronetics to acquire Greenbrook TMS (OTC: GBNHF) in an all-stock deal, doubling revenue to $145M. The combined company expects mid-teens growth in 2025 and 2026, with $15M in cost savings and...
Via
Benzinga
Crude Oil Surges 2%; B. Riley Financial Shares Plunge
August 12, 2024
Via
Benzinga
STIM Stock Earnings: Neuronetics Misses EPS, Misses Revenue for Q2 2024
August 12, 2024
STIM stock results show that Neuronetics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.